Reneo Pharmaceuticals, Inc. Quarterly Debt-to-equity in % from Q3 2021 to Q2 2024

Taxonomy & unit
ratio: %
Description
Debt-to-equity (D/E) ratio is used to evaluate a company's financial leverage and is calculated by dividing a company's total liabilities by its shareholder equity.
Summary
Reneo Pharmaceuticals, Inc. quarterly Debt-to-equity history and growth rate from Q3 2021 to Q2 2024.
  • Reneo Pharmaceuticals, Inc. Debt-to-equity for the quarter ending June 30, 2024 was 10.9 %, a 2.63% increase year-over-year.
Debt-to-equity, Quarterly (%)
Debt-to-equity, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date
Q2 2024 10.9 +0.28 +2.63% Jun 30, 2024
Q1 2024 12.7 +3.31 +35.1% Mar 31, 2024
Q4 2023 14.6 +6.66 +84.4% Dec 31, 2023
Q3 2023 11.7 +4.82 +69.8% Sep 30, 2023
Q2 2023 10.7 +4.95 +86.8% Jun 30, 2023
Q1 2023 9.43 +5.07 +116% Mar 31, 2023
Q4 2022 7.89 +2.86 +56.8% Dec 31, 2022
Q3 2022 6.9 -1.28 -15.6% Sep 30, 2022
Q2 2022 5.7 Jun 30, 2022
Q1 2022 4.35 Mar 31, 2022
Q4 2021 5.04 Dec 31, 2021
Q3 2021 8.19 Sep 30, 2021
* An asterisk sign (*) next to the value indicates that the value is likely invalid.